CHGCY Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 mai 2024 @ 21:59):

Stats
Dagens volum	76 389.00
Gjennomsnittsvolum	183 993
Markedsverdi	54.17B
EPS	$0 ( 2024-04-25 )
Neste inntjeningsdato	( $0 ) 2024-07-25
Last Dividend	$0.189 ( 2021-12-29 )
Next Dividend	$0 ( N/A )
P/E	26.13
ATR14	$0.0120 (0.07%)

Volum Korrelasjon

Lang: 0.07 (neutral)

Kort: 0.33 (neutral)

Signal:(55.489) Neutral

Chugai Pharmaceutical Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Chugai Pharmaceutical Korrelasjon - Valuta/Råvare

0.41
( neutral )

0.00
( neutral )

-0.75
( moderate negative )

-0.30
( neutral )

Chugai Pharmaceutical Økonomi

Annual	2023
Omsetning:	$1 111.37B
Bruttogevinst:	$693.01B (62.36 %)
EPS:	$197.83

FY	2023
Omsetning:	$1 111.37B
Bruttogevinst:	$693.01B (62.36 %)
EPS:	$197.83

FY	2022
Omsetning:	$1 259.95B
Bruttogevinst:	$783.70B (62.20 %)
EPS:	$227.64

FY	2021
Omsetning:	$999.76B
Bruttogevinst:	$661.61B (66.18 %)
EPS:	$92.15

Financial Reports:

No articles found.

Chugai Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Chugai Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 8.15 - good (81.48%) | Divividend Growth Potential Score: 5.60 - Stable (12.07%)

Information

First Dividend	$0.138	2020-12-29
Last Dividend	$0.189	2021-12-29
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	$0.463	--
Avg. Dividend % Per Year	0.00%	--
Score	3.09	--
Div. Sustainability Score	8.15
Div.Growth Potential Score	5.60
Div. Directional Score	6.88	--

Next Divdend (Est)
(2024-09-27)

$0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

3.09

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
WJRYF	Ex Dividend Knight	2023-09-28	Annually	0.00%
LNVGY	Ex Dividend Knight	2023-07-26	Annually	0.00%
CHRYY	Ex Dividend Junior	2023-09-08	Annually	0.00%
SLVYY	Ex Dividend Knight	2023-05-15	Semi-Annually	0.00%
GLAPY	Ex Dividend Knight	2023-08-25	Semi-Annually	0.00%
AGRIP	Ex Dividend Knight	2023-08-31	Quarterly	0.00%
NCBDF	Ex Dividend Junior	2023-09-28	Annually	0.00%
CNTHO	Ex Dividend Knight	2023-09-07	Quarterly	0.00%
TELNY	Ex Dividend Junior	2023-10-19	Semi-Annually	0.00%
HNNMY	Ex Dividend Knight	2023-05-05	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.315	1.500	3.70	5.55	[0 - 0.5]
returnOnAssetsTTM	0.172	1.200	4.27	5.12	[0 - 0.3]
returnOnEquityTTM	0.207	1.500	8.81	10.00	[0.1 - 1]
payoutRatioTTM	0.402	-1.000	5.98	-5.98	[0 - 1]
currentRatioTTM	5.53	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.21	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.937	1.500	0.351	0.526	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	16 118	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	233.57	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	197.34	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.677	1.000	2.05	2.05	[0.2 - 0.8]
operatingProfitMarginTTM	0.420	1.000	3.60	3.60	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.546	0.800	9.69	7.75	[0.5 - 2]
Total Score				8.15

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	12.70	1.000	8.82	0	[1 - 100]
returnOnEquityTTM	0.207	2.50	9.24	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	197.34	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.00876	1.500	9.78	0	[0 - 0.4]
operatingCashFlowPerShareTTM	233.57	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.402	1.500	5.98	-5.98	[0 - 1]
pegRatioTTM	0.00187	1.500	-3.32	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.371	1.000	3.23	0	[0.1 - 0.5]
Total Score				5.60

Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.